论文信息 - IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO - 字舞流文

IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO

F. Turturro | S. Huang | Suping Zhou | K. Nomie | L. Fayad | J. Westin | F. Yan | S. Thirumurthi | H. Chuang | L. Lam | J. Romaguera | M. Ahmed | S. Li | M. Badillo | L. Feng | O. Oriabure | W. Chen | A. Addison | F. Samaniego | L. Zhang | H. Lee | F. Hagemeister | M.L. Wang | L. Wu